<DOC>
	<DOC>NCT01387737</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.</brief_summary>
	<brief_title>Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a randomized, 2-arm, parallel group, open-label study to evaluate the safety and efficacy of TA-7284 in Japanese patients with Type 2 diabetes mellitus, who are not optimally controlled on diet and exercise or with oral anti-hyperglycaemic agent. The patients will receive either TA-7284-Low or TA-7284-High orally alone or in combination with oral anit-hyperglycaemic agent for 52 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Men or women age ≥20 years old Diagnosed with Type 2 diabetes mellitus at least 3 months before screening HbA1c of ≥7.0% and ≤10.0% (monotherapy group) HbA1c of ≥7.0% and ≤10.5% (combination therapy group) Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus Past or current history of severe diabetic complications Fasting plasma glucose &gt; 270 mg/dL before treatment start History of hereditary glucosegalactose malabsorption or primary renal glucosuria Patients requiring insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sodium Glucose Co-Transporter (SGLT2 inhibitor)</keyword>
</DOC>